Types of 23S Ribosomal RNA Point Mutations Affecting Helicobacter pylori Eradication Rates in Clarithromycin-Based...

Area of Science:

• Microbiology
• Genetics
• Pharmacology

Background:

• Clarithromycin resistance in *Helicobacter pylori* is often linked to mutations in the 23S ribosomal ribonucleic acid (rRNA).
• The A2142G and A2143G mutations are the most prevalent, impacting treatment efficacy.
• Understanding the differential impact of these mutations is crucial for optimizing eradication strategies.

Purpose of the Study:

• To compare *H. pylori* eradication rates in patients treated with clarithromycin-based triple therapy.
• To investigate the distinct effects of A2142G and A2143G mutations on treatment outcomes.
• To evaluate the clinical significance of specific 23S rRNA mutations in clarithromycin resistance.

Main Methods:

• Retrospective analysis of data from a randomized controlled trial.
• Comparison of eradication rates based on the presence of specific *H. pylori* 23S rRNA mutations (A2142G and A2143G).
• Meta-analysis of relevant studies involving clarithromycin-based therapy for *H. pylori* with 23S rRNA mutations.

Main Results:

• No significant difference in eradication rates was observed between wild-type *H. pylori* and strains with the A2142G mutation.
• Significantly lower eradication rates were found for strains harboring the A2143G mutation compared to wild-type or A2142G strains.
• Meta-analysis confirmed that the A2143G mutation is associated with a substantially lower *H. pylori* eradication rate.

Conclusions:

• The A2143G mutation is a more significant predictor of clarithromycin triple therapy failure in *H. pylori* eradication than the A2142G mutation.
• *H. pylori* strains with the A2142G mutation can still be effectively eradicated using standard clarithromycin-based triple therapy.
• Treatment guidelines may need to consider the specific 23S rRNA mutation profile for personalized *H. pylori* eradication approaches.